Sign In
Buy MTSR
$70.50
+0 (+0%)
At Close: Feb 12, 2026
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
09:20am, Tuesday, 04'th Nov 2025
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"
09:09am, Tuesday, 04'th Nov 2025
Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a T
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
12:42pm, Monday, 03'rd Nov 2025
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Novo Nordisk says Metsera bid won't raise antitrust issues
12:04pm, Monday, 03'rd Nov 2025
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
11:39am, Monday, 03'rd Nov 2025
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit
Metsera Issues Statement in Response to Litigation
11:02am, Monday, 03'rd Nov 2025
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer: "
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
09:19am, Monday, 03'rd Nov 2025
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Pfizer files second lawsuit against Metsera, Novo Nordisk
08:07am, Monday, 03'rd Nov 2025
Pfizer Inc said on Monday it has filed a second lawsuit against Metsera , its controlling shareholder, and Novo Nordisk in a Delaware federal court, accusing the Danish drugmaker of anticompetitive co
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.
Metsera Issues Statement in Response to Litigation
06:24pm, Friday, 31'st Oct 2025
NEW YORK , Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer: "
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
05:12pm, Friday, 31'st Oct 2025
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
04:43pm, Friday, 31'st Oct 2025
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Pfizer gets US antitrust clearance for Metsera deal
03:55pm, Friday, 31'st Oct 2025
Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera.
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
03:50pm, Friday, 31'st Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improveme
Pfizer could hold a Trump card in its bid for Metsera
06:02am, Friday, 31'st Oct 2025
U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm Metsera, analyst
